Received Mar 29, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | UNK | W008711 | RL |
Varicella zoster virus infection; This spontaneous report was received from a physician and refers to a 3-year-old male patient. The patient's medical history and concomitant therapies were not provided. Current conditions included peanut allergy. On 23-JAN-2023 (reported as at age 1), the patient was vaccinated with varicella virus vaccine live (oka/merck) (VARIVAX) lot number W008711, with no expiration date provided that was verified to be valid with expiration date was established as 14-MAR2024, with sterile diluent administered on right thigh for prophylaxis (strength, specific dosage, dose number, route of administration and date were not provided). On 11-MAR-2025, the patient experienced maximum temperature of 38.0 C and herpes zoster rash involving right ear, scalp and face. Patient had multiple number of lesions distributed on dermatomal in cranial nerve V distribution. On 17-MAR-2025, vesicle/lesion skin sample was collected. On an unknown date in March 2025, he was hospitalized due to the rash with initial concern of Herpes Simplex Virus (HSV) that was found to be Varicella zoster virus (VZV) and on 19-MAR-2025, at hospital discharge was improving from the event (recovering) The causal relationship between the event and suspect vaccine was not provided. Lot # is being requested and will be submitted if received.
Peanut allergy
Sterile diluent
Test Date: 20250311; Test Name: Body temperature; Result Unstructured Data: 38 Cel